A
Akeso Biopharma
A clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies
At a glance
- Status
- Listed
- Listing
- IPO 2020
Open roles
Akeso Biopharma in the Zhongshan ecosystem
The Akeso Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
- AGAlly Bridge Group
- SGShenZhen GTJA Investment Group
- LCLoyal Valley Capital
- SBSino Biopharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
Patents
101 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Akeso Biopharma was the backer or acquirer, 2025–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
1 deals across Akeso Biopharma's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Akeso Biopharma's portfolio, mapped.
See Akeso Biopharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Akeso's ivonescimab shows deep pathological responses in Phase 2 perioperative lung cancer trial
Akeso raises $249M in discounted share placing